ProteLight Pharma
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ProteLight Pharma - overview
Established
2009
Location
Wuxi, Jiangsu, China
Primary Industry
Pharmaceuticals
About
Based in Jiangsu, China and established in 2009, Jiangsu ProteLight Pharmaceutical & Biotechnology Co. , Ltd. , trading as ProteLight Pharma is a biomedical technology company focusing on R&D and production of polypeptide and chemical drugs. In January 2025, ProteLight Pharma raised Series D funding from new investor Guangzhou Cherami Sun Tour Equity Investment Management, Qingdao Guoxin Venture and Efung Capital.
The company focuses on innovative drug development, with a pipeline of first-in-class peptide drugs targeting anti-infection and anti-cancer indications. It holds numerous patents, including PCT international patents and US/EU invention patents. Revenue is generated from sales of innovative peptide drugs, licensing intellectual property, and providing R&D services for pharmaceutical partners.
Current Investors
Hangzhou Binjiang Investment Holding, Yinxinggu Capital, Jiangsu Jincai Investment
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development, Nanomaterials
Website
www.protelight.com
Verticals
Manufacturing
Company Stage
Series D
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.